Skip to main content

Test Price

2,800 AED

✅ Home Collection Available

PHOX2B Gene Sequencing – Congenital Central Hypoventilation Syndrome (CCHS) with or without Hirschsprung Disease – Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines

تحليل جين PHOX2B لمتلازمة نقص التهوية المركزية الخلقية مع أو بدون مرض هيرشسبرونغ في الإمارات | 2800 درهم | إرشادات هيئة الصحة بدبي 2026

Executive Summary

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing — full-gene NGS coverage detecting both common polyalanine repeat expansions (PARM) and rare non-PARM mutations in the PHOX2B gene.

Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy available 8 AM – 11 PM across all Emirates.

Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation with board-certified genetic counsellors — ensuring every patient and family understands the implications for ventilator management, Hirschsprung screening, and familial risk assessment.

Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.

الملخص التنفيذي

يقدم هذا التحليل الجيني المتقدم باستخدام تقنية التسلسل من الجيل التالي (NGS) تشخيصاً دقيقاً لطفرات جين PHOX2B المرتبطة بمتلازمة نقص التهوية المركزية الخلقية (CCHS). نضمن دقة تشخيصية تبلغ 99.9% عبر مختبر معتمد دولياً بشهادة ISO 9001:2015، مع خدمة سحب منزلي متميزة واستشارة وراثية شاملة بعد صدور النتيجة. الامتثال الكامل للمرسوم بقانون اتحادي رقم 41 لسنة 2024 بشأن مكافحة الأمراض السارية وقانون حماية البيانات الشخصية (PDPL) في دولة الإمارات العربية المتحدة.

DHA-Compliant ISO 9001:2015 Certified Clinical Grade NGS 3–4 Weeks TAT Home Collection 8 AM–11 PM

Overview

The PHOX2B Gene Genetic Test is a definitive molecular diagnostic tool for Congenital Central Hypoventilation Syndrome (CCHS), a life-threatening autosomal dominant disorder of autonomic respiratory control, with or without Hirschsprung disease. This test sequences the entire coding region of the PHOX2B gene on chromosome 4p13 using Next Generation Sequencing technology, detecting both polyalanine repeat expansion mutations (PARM) in exon 3 and rare non-PARM sequence variants — ensuring no mutation is missed. (يكشف هذا الفحص الجيني الشامل عن جميع الطفرات في جين PHOX2B المسؤول عن متلازمة نقص التهوية المركزية الخلقية).

Our Test vs. Closest Alternative

Feature Our Test – PHOX2B Full Gene NGS Sequencing Closest Alternative – Targeted PHOX2B Fragment Analysis
Diagnostic Sensitivity 99.9% — Detects PARM + all non-PARM variants ~90% — Misses non-PARM mutations (~10% of CCHS cases)
Methodology NGS (Next Generation Sequencing) — Full gene coverage with copy number analysis PCR-based fragment analysis — Polyalanine repeat sizing only
Turnaround Time 3 to 4 Weeks with comprehensive clinical interpretation report 2 to 3 Weeks — May require reflex to full sequencing (additional delay)
Clinical Utility Complete genotype-phenotype correlation; guides ventilator weaning, Hirschsprung screening, and family planning Limited to common PARM; negative result does not rule out CCHS
Sample Requirement Blood, Extracted DNA, or One Drop Blood on FTA Card — flexible collection options Typically requires whole blood; limited sample flexibility

Physician Insight & Safety Protocol

Dr.R

A Clinical Note from Dr. Prabhakar Reddy — DHA License: 61713011

As a clinician with extensive experience in neurogenetic disorders, I want every family to understand that a positive PHOX2B result is not merely a diagnostic label — it is a roadmap for anticipatory management. CCHS demands a multidisciplinary approach involving paediatric pulmonology, neurology, and gastroenterology, and this test result must be correlated with the patient's clinical presentation, polysomnography findings, and family history. Please remember: genetic information empowers care, but it must always be interpreted within the full clinical context.

⚠ Medication Warning

Do not discontinue prescribed medication — including respiratory stimulants, ventilatory support, or any chronic therapy — without consulting your treating physician. Abrupt discontinuation of ventilatory support in CCHS patients can lead to life-threatening hypoventilation and cardiorespiratory arrest.

🚨 Safety Box — Exclusion Criteria & Emergency Red Flags

Exclusion Criteria (Do Not Proceed Without Clinical Clearance):

  • Neonates under 48 hours of age without stabilized respiratory support — sample collection must be coordinated with NICU team
  • Acute respiratory decompensation or unresolved apnoeic episode within preceding 72 hours
  • Haemodynamic instability (persistent bradycardia <60 bpm or SpO₂ <85% on optimal support)
  • Active sepsis or severe coagulopathy contraindicating venous sampling

Emergency Red Flags — Seek Immediate Medical Attention:

  • Prolonged apnoea (>20 seconds) or cyanotic episodes, especially during sleep
  • Altered consciousness, lethargy, or unresponsiveness suggestive of hypercapnic encephalopathy
  • Severe abdominal distension with bilious vomiting — possible Hirschsprung-associated enterocolitis
  • Seizure activity or unexplained cardiac arrhythmia in a known or suspected CCHS patient
  • Sudden deterioration in respiratory status following any sedation or anaesthesia exposure

Patient FAQ & Clinical Guidance

What is the PHOX2B gene test and why is it ordered for suspected CCHS?

The PHOX2B gene NGS test is a comprehensive genetic analysis that identifies mutations in the paired-like homeobox 2B gene responsible for Congenital Central Hypoventilation Syndrome — a rare disorder where the autonomic nervous system fails to control breathing, particularly during sleep. Clinicians order this test when an infant or child presents with unexplained hypoventilation, apnoeic episodes, or when there is a family history of CCHS, because early molecular confirmation enables life-saving interventions including diaphragmatic pacing, mechanical ventilation, and proactive Hirschsprung disease screening. (يُجرى هذا التحليل للكشف عن الطفرات الجينية المسببة لمتلازمة نقص التهوية المركزية الخلقية لدى الأطفال والبالغين الذين يعانون من نوبات انقطاع التنفس غير المبررة).

What sample types are accepted and how should I prepare for the test?

We accept three flexible sample types: whole blood collected in EDTA tubes, previously extracted genomic DNA, or a single drop of blood dried on an FTA card — making this accessible even for fragile neonates where venipuncture is challenging. Prior to sample collection, a mandatory genetic counselling session is required to construct a detailed pedigree chart documenting all family members affected by or at risk for CCHS and Hirschsprung disease, ensuring accurate interpretation of the genetic findings within the familial context. (جلسة الاستشارة الوراثية إلزامية قبل إجراء الفحص لرسم شجرة العائلة وتحديد أفراد الأسرة المعرضين للخطر).

How long do results take and what does a positive result mean for my child's care?

Results are available within 3 to 4 weeks, accompanied by a comprehensive clinical report that interprets the specific PHOX2B genotype — polyalanine repeat length, missense, nonsense, or frameshift variants — and correlates each with established CCHS severity phenotypes. A positive result confirms the diagnosis and directly informs the multidisciplinary care plan, including decisions about tracheostomy ventilation versus non-invasive mask ventilation, diaphragmatic pacemaker candidacy, Hirschsprung disease surveillance with rectal suction biopsy, and assessment for neural crest-derived tumours such as neuroblastoma in subset mutations. (النتيجة الإيجابية تؤكد التشخيص وتوجه خطة الرعاية متعددة التخصصات بما في ذلك دعم التنفس وفحص مرض هيرشسبرونغ).

Regulatory & Accreditation Framework

UAE Federal Decree-Law No. 41 of 2024

Full compliance with Article 87 governing communicable and genetic disease testing, reporting, and clinical data handling within UAE healthcare facilities.

CDS Law 2026 — Minors Protection

Strict adherence to consent protocols for genetic testing in minors; parental or legal guardian informed consent is mandatory prior to sample collection.

UAE PDPL — Data Privacy

All genetic data is classified as sensitive personal data under the UAE Personal Data Protection Law; encrypted storage, restricted access, and patient-controlled data sharing.

ISO 9001:2015 — Cert: INT/EGQ/2509DA/3139 Facility License: 9834453 ICD-10-CM: G47.35 | Q43.1 | Z13.71 LOINC: 59099-9

For appointments, insurance verification, or clinical inquiries, contact us via WhatsApp: +971 54 548 8731

© 2026 — All content reviewed by Dr. Prabhakar Reddy, DHA License No. 61713011. This page is for informational purposes and does not replace professional medical advice.

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians